肿瘤细胞治疗研究
英文原题：Dual-target CAR-T cell therapy: latest updates from the 2025 ASH annual meeting.
双靶点CAR-T（CAR-T）细胞疗法已成为一种有前景的策略，用以解决单靶点 CAR-T 方法的关键局限，包括抗原异质性和抗原阴性逃逸。
双靶点CAR-T（CAR-T）细胞疗法已成为克服单靶点CAR-T局限的有前景策略，包括抗原异质性及抗原阴性逃逸。近期研究报道了双靶点CAR-T工程化的快速进展，涵盖多种受体结构、逻辑门控设计和新型制造平台。临床前数据表明，该疗法在B细胞恶性肿瘤、急性髓系白血病及自身免疫病模型中可改善疾病控制。本文总结了2025年美国血液学会（ASH）年会上报告的双靶点CAR-T细胞疗法临床前研究及临床试验最新进展。
Dual-target chimeric antigen receptor T (CAR-T) cell therapy has emerged as a promising strategy to address the key limitations of single-target CAR-T approaches, including antigen heterogeneity and antigen-negative escape. Recent studies have reported rapid progress in the engineering of dual-target CAR-T, incorporating diverse receptor architectures, logic-gated designs, and novel manufacturing platforms. Preclinical data demonstrate improved disease control across B-cell malignancies, acute myeloid leukemia, and autoimmune disease models. Here, we summarize the latest advancements in the preclinical investigations and clinical trials of dual-target CAR-T cell therapy presented at the 2025 ASH annual meeting.
MEMBER ACCOUNT
登录成功会直接打开下一页。
